Accessibility: Skip TopNav
Data Update from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of January 6, 2025
Source: Immuneering Corporation
Format
PNG
Source
Immuneering Corporation
Downloads
Original
Large
Medium
Small